Abstract
Purpose: To review the most important metabolic effects and clinical safety data of subthreshold micropulse diode laser (D-MPL) in diabetic macular edema (DME).
Methods: Review of the literature about the mechanisms of action and role of D-MPL in DME.
Results: The MPL treatment does not damage the retina and is selectively absorbed by the retinal pigment epithelium (RPE). MPL stimulates secretion of different protective cytokines by the RPE. No visible laser spots on the retina were noted on any fundus image modality in different studies, and there were no changes of the outer retina integrity. Mean central retinal sensitivity (RS) increased in subthreshold micropulse diode laser group compared to standard ETDRS photocoagulation group.
Conclusions: MPL is a new, promising treatment option in DME, with both infrared and yellow wavelengths using the less aggressive duty cycle (5%) and fixed power parameters. It appears to be safe from morphologic and functional point of view in mild center involving DME.
Keywords: Diabetic macular edema, diabetic retinopathy, fluorescein angiography, fundus autofluorescence, microperimetry, laser treatment, optical coherence tomography, subthreshold micropulse laser, retinal safety.
Current Medicinal Chemistry
Title:Subthreshold Laser Therapy for Diabetic Macular Edema: Metabolic and Safety Issues
Volume: 20 Issue: 26
Author(s): Stela Vujosevic, Ferdinando Martini, Enrica Convento, Evelyn Longhin, Olympia Kotsafti, Raffaele Parrozzani and Edoardo Midena
Affiliation:
Keywords: Diabetic macular edema, diabetic retinopathy, fluorescein angiography, fundus autofluorescence, microperimetry, laser treatment, optical coherence tomography, subthreshold micropulse laser, retinal safety.
Abstract: Purpose: To review the most important metabolic effects and clinical safety data of subthreshold micropulse diode laser (D-MPL) in diabetic macular edema (DME).
Methods: Review of the literature about the mechanisms of action and role of D-MPL in DME.
Results: The MPL treatment does not damage the retina and is selectively absorbed by the retinal pigment epithelium (RPE). MPL stimulates secretion of different protective cytokines by the RPE. No visible laser spots on the retina were noted on any fundus image modality in different studies, and there were no changes of the outer retina integrity. Mean central retinal sensitivity (RS) increased in subthreshold micropulse diode laser group compared to standard ETDRS photocoagulation group.
Conclusions: MPL is a new, promising treatment option in DME, with both infrared and yellow wavelengths using the less aggressive duty cycle (5%) and fixed power parameters. It appears to be safe from morphologic and functional point of view in mild center involving DME.
Export Options
About this article
Cite this article as:
Vujosevic Stela, Martini Ferdinando, Convento Enrica, Longhin Evelyn, Kotsafti Olympia, Parrozzani Raffaele and Midena Edoardo, Subthreshold Laser Therapy for Diabetic Macular Edema: Metabolic and Safety Issues, Current Medicinal Chemistry 2013; 20 (26) . https://dx.doi.org/10.2174/09298673113209990030
DOI https://dx.doi.org/10.2174/09298673113209990030 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sirolimus Eluting Stent: A New Era in Interventional Cardiology?
Current Pharmaceutical Design Basic and Clinical Aspects of Gene Therapy for Retinopathy Induced by Diabetes
Current Gene Therapy Directed Differentiation of Pluripotent Cells Towards Therapeutic Stem Cells
Recent Patents on Regenerative Medicine Stroke in Women
Recent Patents on Cardiovascular Drug Discovery CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Current Pharmaceutical Design Update on Pharmacologic Retinal Vascular Toxicity
Current Pharmaceutical Design Anthocyanins As Modulators of Cell Redox-Dependent Pathways in Non-Communicable Diseases
Current Medicinal Chemistry Endothelial Progenitor Cells as Potential Drug Targets
Current Drug Targets - Cardiovascular & Hematological Disorders Drug Delivery to the Back of the Eye Following Topical Administration: An Update on Research and Patenting Activity
Recent Patents on Drug Delivery & Formulation Effect of Homocysteinylation on Structure, Chaperone Activity and Fibrillation Propensity of Lens Alpha-crystallin
Protein & Peptide Letters Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design Inflammation and Immunology of the Vitreoretinal Compartment
Inflammation & Allergy - Drug Targets (Discontinued) Subtypes of Antiphospholipid Antibodies in Neurologic Disorders: An Observational Study
Current Rheumatology Reviews Anti-VEGF Treatment in Corneal Diseases
Current Drug Targets Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research Clinical Evidence of Intravitreal Triamcinolone Acetonide in the Management of Age-Related Macular Degeneration
Current Drug Targets Pharmacogenomics of Open-Angle Glaucoma
Current Pharmacogenomics and Personalized Medicine CREG: A Possible Candidate for Both Prevention and Treatment of Proliferative Vascular Disease
Current Molecular Medicine Models for the Study of Angiogenesis
Current Pharmaceutical Design Involvement of Coagulation and Hemostasis in Inflammatory Bowel Diseases
Current Vascular Pharmacology